Akebia Therapeutics Inc
F:AX9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Akebia Therapeutics Inc
F:AX9
|
US |
|
A
|
Azelis Group NV
F:2R7
|
BE |
|
Aeroports de Paris SA
OTC:ARRPY
|
FR |
|
B
|
Bangkok Commercial Asset Management PCL
SET:BAM
|
TH |
|
M
|
Mosaic Co
XMUN:02M
|
US |
|
T
|
Thales SA
XMUN:CSF
|
FR |
|
Eastfield Resources Ltd
XTSX:ETF
|
CA |
|
TherapeuticsMD Inc
NASDAQ:TXMD
|
US |
|
STRABAG SE
OTC:STBBF
|
AT |
|
Z
|
Zhejiang Expressway Co Ltd
F:ZHJ
|
CN |
|
B
|
Bidvest Group Ltd
XMUN:NQL1
|
ZA |
|
R
|
Roper Technologies Inc
F:ROP
|
US |
|
P
|
PLDT Inc
F:PLO
|
PH |
|
N
|
Nippon Steel Corp
F:NPSA
|
JP |
Wall St Price Targets
AX9 Price Targets Summary
Akebia Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for AX9 is 3.6114 EUR with a low forecast of 0.894 EUR and a high forecast of 5.5764 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AX9's stock price target?
Price Target
3.6114
EUR
According to Wall Street analysts, the average 1-year price target for AX9 is 3.6114 EUR with a low forecast of 0.894 EUR and a high forecast of 5.5764 EUR.
What is the Revenue forecast for Akebia Therapeutics Inc?
Projected CAGR
9%
The compound annual growth rate for Revenue over the next 8 years is 9%.
What is the Gross Profit forecast for Akebia Therapeutics Inc?
Projected CAGR
-6%
The compound annual growth rate for Gross Profit over the next 3 years is -6%.
What is the Operating Income forecast for Akebia Therapeutics Inc?
Projected CAGR
34%
The compound annual growth rate for Operating Income over the next 8 years is 34%.